April 16, 2018 feichang 0Comment

National Drug talks this month 3 prices into NCMS fell over 50% original title: National Drug talks this month JINGWAH included in the new rural cooperative Times News (reporter Ma Jinfeng) yesterday, the reporter learned from the National Health Planning Commission, Planning Commission in conjunction with the Ministry of Finance jointly issued a notice, request the shot in before the end of October this year, the state will be included in the new rural cooperative medicine talks reimbursement drug list. In May this year, the National Health Planning Commission announced the results of the first batch of national drug price negotiations, 3 kinds of drugs negotiated price decline in more than 50%. It is understood that the first batch of national drug price negotiations of drugs, including chronic hepatitis B drug tenofovir, first-line treatment of non-small cell lung cancer targeted therapy of icotinib and gefitinib. Compared with the prior public hospital drug purchase price, 3 negotiation prices fell more than 50%, among them, for the treatment of chronic hepatitis B tenofovir reached 67%. Yesterday, the reporter learned from the National Health Planning Commission, recently, the State Planning Commission in conjunction with the Ministry of Finance jointly issued the "on notice of the State Drug negotiations with the new rural cooperative medical reimbursement policy convergence" (hereinafter referred to as the "notice"). "Notice" proposed, according to the results of the national drug price negotiations in a timely manner to adjust the NCMS reimbursement drug catalog. The provinces have not yet adjusted, according to the local economic development, the level of the NCMS funding, the ability of medical services, where the change of disease spectrum and the actual situation, based on the implementation of negotiations, and strive to national bargaining drugs into the NCMS reimbursement drug list before the end of October 2016, and reported to the State Planning Commission grassroots division for the record. Fund expenditure pressure in the region, you can choose part of the species or from a serious illness insurance. Read the rest of the health insurance policy implementation is still "uneven" convergence of patent medicine, expensive imported drugs is one of the reasons why people expensive, the negotiating team expert, vice president of Beijing Ditan Hospital in that country through negotiate lower drug prices can really make people get the benefits, but really difficult to fundamentally solve the problem of your medication, medication also, we need to strengthen the cohesion and other aspects of drug approval, medical insurance policy. Negotiations have been published in the past 5 months, but due to the convergence of medical insurance on the issue, the implementation of this policy in the local uneven". At the end of August, Yunnan, Hainan, Guangxi docking and other 17 provinces completed negotiations for drugs and Medicare reimbursement, the remaining provinces have not included in the Medicare drug. Because some provinces appeared between the price gap, resulting in some provinces were to buy medicine. Some experts said that once the negotiations drugs can not enter the health insurance, will form a bad demonstration effect". The price of the pharmaceutical companies to enter the insurance after the purchases of low-cost exchange, if not into the health insurance, there is no price for pharmaceutical companies are willing to negotiate. Editor: Wang Haocheng相关的主题文章: